Tempus AI (NASDAQ:TEM) Stock Price Down 5.7% on Insider Selling

Tempus AI, Inc. (NASDAQ:TEM)’s stock price fell 5.7% on Monday following insider selling activity. The company traded as low as $33.42 and last traded at $33.53. 1,226,691 shares changed hands during trading, a decline of 22% from the average session volume of 1,575,843 shares. The stock had previously closed at $35.54.

Specifically, CEO Eric P. Lefkofsky sold 187,655 shares of the firm’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $37.54, for a total value of $7,044,568.70. Following the transaction, the chief executive officer now owns 9,557,283 shares of the company’s stock, valued at $358,780,403.82. This trade represents a 1.93 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Ryan Fukushima sold 3,500 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $40.23, for a total value of $140,805.00. Following the completion of the sale, the chief operating officer now directly owns 1,003,707 shares in the company, valued at approximately $40,379,132.61. This trade represents a 0.35 % decrease in their position. The disclosure for this sale can be found here. In related news, EVP Andrew Polovin sold 1,130 shares of the company’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $40.23, for a total transaction of $45,459.90. Following the completion of the transaction, the executive vice president now directly owns 244,955 shares in the company, valued at $9,854,539.65. This represents a 0.46 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Piper Sandler restated a “neutral” rating and set a $70.00 price target (up previously from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Guggenheim started coverage on Tempus AI in a report on Monday, December 9th. They issued a “buy” rating and a $74.00 price objective for the company. Loop Capital lifted their target price on Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday, October 15th. Bank of America increased their price target on Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a research note on Friday, December 13th. Finally, Wolfe Research assumed coverage on shares of Tempus AI in a research note on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective on the stock. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $56.00.

Tempus AI Stock Performance

The company’s 50-day moving average price is $50.88. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17.

Institutional Trading of Tempus AI

A number of large investors have recently added to or reduced their stakes in the business. Northwestern University acquired a new stake in Tempus AI during the 2nd quarter worth about $491,000. Alphabet Inc. purchased a new position in shares of Tempus AI in the second quarter worth approximately $54,289,000. Pier Capital LLC acquired a new stake in shares of Tempus AI during the second quarter valued at approximately $2,301,000. Federated Hermes Inc. purchased a new stake in shares of Tempus AI in the 2nd quarter valued at approximately $19,886,000. Finally, Revolution Growth Management Company Inc. acquired a new position in Tempus AI in the 2nd quarter worth approximately $128,133,000. 24.22% of the stock is currently owned by institutional investors.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.